Skip to main content

Vibegron Disease Interactions

There are 3 disease interactions with vibegron.

Moderate

Vibegron (applies to vibegron) liver disease

Moderate Potential Hazard, Moderate plausibility.

Vibegron is not recommended in patients with severe liver dysfunction (Child-Pugh C), as it has not been studied in these patients. No dose adjustment for vibegron is recommended for patients with mild to moderate liver dysfunction (Child-Pugh A and B).

References (1)
  1. (2024) "Product Information. Gemtesa (vibegron)." Urovant Sciences, Inc, SUPPL-11
Moderate

Vibegron (applies to vibegron) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Vibegron is not recommended in patients with estimated GFR less than 15 mL/min/1.73 m2 (with or without hemodialysis), as it has not been studied in these patients. No dose adjustment for vibegron is recommended for patients with mild, moderate, or severe renal dysfunction (estimated GFR 15 to less than 90 mL/min/1.73 m2).

References (1)
  1. (2024) "Product Information. Gemtesa (vibegron)." Urovant Sciences, Inc, SUPPL-11
Moderate

Vibegron (applies to vibegron) urinary retention

Moderate Potential Hazard, Moderate plausibility.

Urinary retention has been reported with vibegron. The risk of urinary retention may be increased in patients with bladder outlet obstruction and in those taking muscarinic antagonist medications to treat overactive bladder. Patients should be monitored for signs/symptoms of urinary retention, especially those with increased risk. The use of vibegron should be discontinued if urinary retention develops.

References (1)
  1. (2024) "Product Information. Gemtesa (vibegron)." Urovant Sciences, Inc, SUPPL-11

Switch to consumer interaction data

Vibegron drug interactions

There are 16 drug interactions with vibegron.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer